India Reschedules Drug Export Track And Trace Plan
This article was originally published in SRA
India has deferred the implementation of its track and trace system for pharmaceutical exports - measures that are essentially aimed at curbing the menace of fake products and also enhance supply-chain safety1.
You may also be interested in...
A government plan aimed at putting in place an e-platform to regulate the sale of medicines in India, is expected to bolster end-to-end traceability and help lower the risk of fake drugs in the supply chain. But the platform’s proposed revenue model appears to be a sticking point, at least for now, among other tricky areas.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.